Clinical trials
Phase 3 Stroke trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 8 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Terminated | 15 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| University of Calgary | 4 |
| Allergan | 3 |
| AstraZeneca | 3 |
| Bayer | 3 |
| Columbia University | 3 |
| NoNO Inc. | 3 |
| Population Health Research Institute | 3 |
| Toronto Rehabilitation Institute | 3 |
| Boehringer Ingelheim | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stroke | 66 |
| Myocardial Infarction | 17 |
| Atrial Fibrillation | 14 |
| Ischemic Stroke | 12 |
| Cardiovascular Diseases | 11 |
| Heart Diseases | 6 |
| Ischemic Attack, Transient | 6 |
| Thromboembolism | 5 |
| Coronary Artery Disease | 4 |
| Heart Failure | 4 |
Trials
Showing 1 to 25 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.